Nutraceuticals for infants with retinopathy of prematurity: perspective

Authors

  • Anakin Chu Kwan Lai
  • Connie Lai
  • Nicholas Fung
  • Amy Lo HKU

Keywords:

Blindness, Child, Hyperoxia, Hypoxia, Retinal neovascularization

Abstract

Retinopathy of prematurity (ROP) is one of the most common causes of childhood blindness worldwide. Its prevalence is rising as more premature infants are surviving owing to advances in neonatal care. The current treatments for ROP are invasive and may increase the risk of future eye complications. Nutraceuticals (dietary oils, carotenoids, and vitamin supplements) are generally safe for use in children without detrimental adverse effects. Research has demonstrated nutraceuticals’ anti-angiogenesis properties and their potential to protect against ROP. Dietary oils suppress inflammation and neovascularization in ROP models when administered intravenously. Carotenoids, such as lutein, promote retinal revascularization in mice. Vitamin A, C, and E supplements are unable to prevent ROP pathogenesis, despite well-documented antioxidative effects. The discrepancy between laboratory and clinical trial results may be due to differences in the dosage that can affect the eye, the outcome measurements used, and the presence of confounders in clinical trials. Future studies should investigate the short- and long-term effects of nutraceuticals on infants’ vision.

References

Gilbert C, Foster A. Childhood blindness in the context of VISION 2020--the right to sight. Bull World Health Organ 2001;79:227-32.

Kong L, Fry M, Al-Samarraie M, Gilbert C, Steinkuller PG. An update on progress and the changing epidemiology of causes of childhood blindness worldwide. J AAPOS 2012;16:501-7.

Gilbert C. Changing challenges in the control of blindness in children. Eye (Lond) 2007;21:1338-43.

Baker JP. The incubator and the medical discovery of the premature infant. J Perinatol 2000;5:321-8.

Austeng D, Källen KBM, Uwe W. Ewald M, Jakobsson PG, Holmström GE. incidence of retinopathy of prematurity in infants born before 27 weeks' gestation in Sweden. Arch Ophthalmol 2009;127:1315-9.

Iu LP, Lai CH, Fan MC, Wong IY, Lai JS. Screening for retinopathy of prematurity and treatment outcome in a tertiary hospital in Hong Kong. Hong Kong Med J 2017;23:41-7.

Chawanpaiboon S, Vogel JP, Moller AB, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Glob Health 2019;7:e37-e46.

Tsang JKW, Liu J, Lo ACY. Vascular and neuronal protection in the developing retina: potential therapeutic targets for retinopathy of prematurity. Int J Mol Sci 2019;20:4321.

Clark D, Mandal K. Treatment of retinopathy of prematurity. Early Hum Dev 2008;84:95-9.

Lenis TL, Gunzenhauser RC, Fung SSM, et al. Myopia and anterior segment optical coherence tomography findings in laser-treated retinopathy of prematurity eyes. J AAPOS 2020;24:86.e1-e7.

Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012;153:327-33.e1.

Hoerster R, Muether P, Dahlke C, et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol 2013;91:e74-5.

Morin J, Luu TM, Superstein R, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics 2016;137:e20153218.

Tsang JKW, Wolf SA, Pompoes IM, et al. Potential effects of nutraceuticals in retinopathy of prematurity. Life (Basel) 2021;11:79.

Shahidi F. Nutraceuticals, Functional foods and dietary supplements in health and disease. J Food Drug Anal 2012;20:226-30.

Kalra EK. Nutraceutical: definition and introduction. AAPS PharmSci 2003;5:E25.

Chauhan B, Kumar G, Kalam N, Ansari SH. Current concepts and prospects of herbal nutraceutical: a review. J Adv Pharm Technol Res 2013;4:4-8.

Riccioni G. Carotenoids and cardiovascular disease. Curr Atheroscler Rep 2009;11:434-9.

Rubin LP, Chan GM, Barrett-Reis BM, et al. Effect of carotenoid supplementation on plasma carotenoids, inflammation and visual development in preterm infants. J Perinatol 2012;32:418-24.

Kapoor B, Kapoor D, Gautam S, Singh R, Bhardwaj S. Dietary polyunsaturated fatty acids (PUFAs): uses and potential health benefits. Curr Nutr Rep 2021;10:232-42.

Shimazawa M, Nakajima Y, Mashima Y, Hara H. Docosahexaenoic acid (DHA) has neuroprotective effects against oxidative stress in retinal ganglion cells. Brain Res 2009;1251:269-75.

Fu Z, Lofqvist CA, Shao Z, et al. Dietary omega-3 polyunsaturated fatty acids decrease retinal neovascularization by adipose-endoplasmic reticulum stress reduction to increase adiponectin. Am J Clin Nutr 2015;101:879-88.

SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res 2005;24:87-138.

Lofqvist CA, Najm S, Hellgren G, et al. Association of retinopathy of prematurity with low levels of arachidonic acid: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 2018;136:271-7.

Najm S, Lofqvist C, Hellgren G, et al. Effects of a lipid emulsion containing fish oil on polyunsaturated fatty acid profiles, growth and morbidities in extremely premature infants: a randomized controlled trial. Clin Nutr ESPEN 2017;20:17-23.

Pawlik D, Lauterbach R, Turyk E. Fish-oil fat emulsion supplementation may reduce the risk of severe retinopathy in VLBW infants. Pediatrics 2011;127:223-8.

Koletzko B, Lien E, Agostoni C, et al. The roles of long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy: review of current knowledge and consensus recommendations. J Perinat Med 2008;36:5-14.

Makrides M, Gibson RA, McPhee AJ, et al. Neurodevelopmental outcomes of preterm infants fed high-dose docosahexaenoic acid: a randomized controlled trial. JAMA 2009;301:175-82.

Beken S, Dilli D, Fettah ND, Kabatas EU, Zenciroglu A, Okumus N. The influence of fish-oil lipid emulsions on retinopathy of prematurity in very low birth weight infants: a randomized controlled trial. Early Hum Dev 2014;90:27-31.

Tu CF, Lee CH, Chen HN, Tsao LY, Chen JY, Hsiao CC. Effects of fish oil-containing lipid emulsions on retinopathy of prematurity in very low birth weight infants. Pediatr Neonatol 2020;61:224-30.

Bernabe-Garcia M, Villegas-Silva R, Villavicencio-Torres A, et al. Enteral docosahexaenoic acid and retinopathy of prematurity: a randomized clinical trial. JPEN J Parenter Enteral Nutr 2019;43:874-82.

Hellstrom A, Nilsson AK, Wackernagel D, et al. Effect of enteral lipid supplement on severe retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr 2021;175:359-67.

Patel RM. Short- and long-term outcomes for extremely preterm infants. Am J Perinatol 2016;33:318-28.

Hartnett ME. The prematurity of recommending particular polyunsaturated fatty acid supplements for retinopathy of prematurity. JAMA Ophthalmol 2018;136:277-8.

Bernstein PS, Arunkumar R. The emerging roles of the macular pigment carotenoids throughout the lifespan and in prenatal supplementation. J Lipid Res 2021;62:100038.

Arunkumar R, Gorusupudi A, Bernstein PS. The macular carotenoids: a biochemical overview. Biochim Biophys Acta Mol Cell Biol Lipids 2020;1865:158617.

Li SY, Fung FK, Fu ZJ, Wong D, Chan HH, Lo AC. Anti-inflammatory effects of lutein in retinal ischemic/hypoxic injury: in vivo and in vitro studies. Invest Ophthalmol Vis Sci 2012;53:5976-84.

Li SY, Lo AC. Lutein protects RGC-5 cells against hypoxia and oxidative stress. Int J Mol Sci 2010;11:2109-17.

Alves-Rodrigues A, Shao A. The science behind lutein. Toxicol Lett 2004;150:57-83.

Ranard KM, Jeon S, Mohn ES, Griffiths JC, Johnson EJ, Erdman JW Jr. Dietary guidance for lutein: consideration for intake recommendations is scientifically supported. Eur J Nutr 2017;56(Suppl 3):37-42.

Fu Z, Meng SS, Burnim SB, Smith LE, Lo AC. Lutein facilitates physiological revascularization in a mouse model of retinopathy of prematurity. Clin Exp Ophthalmol 2017;45:529-38.

Dani C, Lori I, Favelli F, et al. Lutein and zeaxanthin supplementation in preterm infants to prevent retinopathy of prematurity: a randomized controlled study. J Matern Fetal Neonatal Med 2012;25:523-7.

Manzoni P, Guardione R, Bonetti P, et al. Lutein and zeaxanthin supplementation in preterm very low-birth-weight neonates in neonatal intensive care units: a multicenter randomized controlled trial. Am J Perinatol 2013;30:25-32.

Romagnoli C, Giannantonio C, Cota F, et al. A prospective, randomized, double blind study comparing lutein to placebo for reducing occurrence and severity of retinopathy of prematurity. J Matern Fetal Neonatal Med 2011;24(Suppl 1):147-50.

Mactier H, McCulloch DL, Hamilton R, et al. Vitamin A supplementation improves retinal function in infants at risk of retinopathy of prematurity. J Pediatr 2012;160:954-9.e1.

Caritá AC, Fonseca-Santos B, Shultz JD, Michniak-Kohn B, Chorilli M, Leonardi GR. Vitamin C: one compound, several uses. Advances for delivery, efficiency and stability. Nanomedicine 2020;24:102117.

Herrera E, Barbas C. Vitamin E: action, metabolism and perspectives. J Physiol Biochem 2001;57:43-56.

Romero-Maldonado S, Montoya-Estrada A, Reyes-Munoz E, et al. Efficacy of water-based vitamin E solution versus placebo in the prevention of retinopathy of prematurity in very low birth weight infants: a randomized clinical trial. Medicine 2021;100:e26765.

Sun H, Cheng R, Wang Z. Early vitamin A supplementation improves the outcome of retinopathy of prematurity in extremely preterm infants. Retina (Phila) 2020;40:1176-84.

Loerch JD, Underwood BA, Lewis KC. Response of plasma levels of vitamin A to a dose of vitamin A as an indicator of hepatic vitamin A reserves in rats. J Nutr 1979;109:778-86.

Perrone S, Negro S, Tataranno ML, Buonocore G. Oxidative stress and antioxidant strategies in newborns. J Matern Fetal Neonatal Med 2010;23(Suppl 3):63-5.

Phelps DL, Rosenbaum AL, Isenberg SJ, Leake RD, Dorey FJ. Tocopherol efficacy and safety for preventing retinopathy of prematurity: a randomized, controlled, double-masked trial. Pediatrics 1987;79:489-500.

Halliwell B. Vitamin C: antioxidant or pro-oxidant in vivo? Free Radic Res 1996;25:439-54.

Carr A, Frei B. Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J 1999;13:1007-24.

Darlow BA, Buss H, McGill F, Fletcher L, Graham P, Winterbourn CC. Vitamin C supplementation in very preterm infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2005;90:F117-22.

Silvers KM, Gibson AT, Powers HJ. High plasma vitamin C concentrations at birth associated with low antioxidant status and poor outcome in premature infants. Arch Dis Child Fetal Neonatal Ed 1994;71:F40-4.

Cao Y, Cao R. Angiogenesis inhibited by drinking tea. Nature 1999;398:381.

Tsuda T. Dietary anthocyanin-rich plants: biochemical basis and recent progress in health benefits studies. Mol Nutr Food Res 2012;56:159-70.

Wang Y, Zhao L, Lu F, et al. Retinoprotective effects of bilberry anthocyanins via antioxidant, anti-inflammatory, and anti-apoptotic mechanisms in a visible light-induced retinal degeneration model in pigmented rabbits. Molecules 2015;20:22395-410.

Lee YM, Kim CS, Jo K, Sohn EJ, Kim JS, Kim J. Inhibitory effect of Samul-tang on retinal neovascularization in oxygen-induced retinopathy. BMC Complement Altern Med 2015;15:271.

Lee YM, Lee YR, Kim CS, et al. Effect of Guibi-Tang, a traditional herbal formula, on retinal neovascularization in a mouse model of proliferative retinopathy. Int J Mol Sci 2015;16:29900-10.

Downloads

Published

2024-01-02

How to Cite

1.
Lai ACK, Lai C, Fung N, Lo A. Nutraceuticals for infants with retinopathy of prematurity: perspective. Hong Kong J Ophthalmol [Internet]. 2024Jan.2 [cited 2024Jun.15];27(2). Available from: https://hkjo.hk/index.php/hkjo/article/view/358

Issue

Section

Perspective

Most read articles by the same author(s)